Generate QR code
Open Access
Subscription Access
Tactics of management of superficial vein thrombosis
https://doi.org/10.30629/0023-2149-2026-104-3-184-194
Abstract
Superficial vein thrombosis (SVT) is a common clinical condition that carries with it significant risk of propagation of thrombus, recurrence, and, most concerning, subsequent venous thromboembolism (VTE). Conservative therapy with nonsteroidal antiinflammatory medication and heat does not prevent extension of thrombus or protect against recurrent or future VTE in patients with extensive SVT thrombotic segment of at least 5 cm in length. To prevent future thromboembolic events, anticoagulation has become the treatment of choice for extensive SVT. The aim of the review was to provide evidence-based, up-to-date information on the epidemiology, risk factors, diagnosis, and treatment of patients with SVT. A comprehensive literature search was conducted to identify all randomized controlled trials (RCTs) that addressed the epidemiology and treatment of SVT. RCT publications were identified using the MEDLINE database of English-language medical literature from 2002 to February 2025. The key search terms used were superficial vein thrombosis, treatment of superficial vein thrombosis, medical and surgical treatment of SVT. The search was performed using both single and combinations of terms.
About the Author
A. B. Sugraliyev
Asfendiyarov Kazakh National Medical University
Kazakhstan
Kazakhstan
Akhmetzhan B. Sugrаliyev — Candidate of Medical Sciences; Associate Professor; Head of Internal Diseases department
Almaty
References
1. Mangiafi co M., Costanzo L. Superfi cial Venous Thrombosis: A Comprehensive Review. Healthcare. 2024;12(500):1–16. DOI: 10.3390/healthcare12040500
2. Cosmi B. Management of superfi cial vein thrombosis J. Thromb. Haemost. 2015;13:1175–83. DOI: 10.1111/jth.12986
3. Di Nisio M., Camporese G., Di Micco P. Treatment of Superfi cial Vein Thrombosis: Recent Advances, Unmet Needs and Future Directions. Healthcare. 2024;12:1517. DOI: 10.3390/healthcare12151517
4. Di Minno M.N., Ambrosino P., Ambrosini F. et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superfi cial vein thrombosis: a systematic review and meta-analysis. J. Thromb. Haemost. 2016;14(5):964–72. DOI: 10.1111/jth.13279. PMid:26845754
5. Raffetto J.D., Eberhardt R.T. Benefi t of anticoagulation for the treatment of lower extremity superfi cial venous thrombosis. J. Vasc. Surg: Venous and Lym. Dis. 2015;3:236–41. DOI: 10.1016/j.jvsv.2014.11.005. PMid:26993846.
6. Jørgensen C.T., Brækkan S.K., Førsund E. et al. Incidence of venous thromboembolism, recurrence, and bleeding after isolated superfi cial vein thrombosis: Findings from the Venous Thrombosis Registry in Østfold Hospital. J. Thromb. Haemost. 2024;22:526–533. DOI: 10.1016/j.jtha.2023.10.017
7. Di Minno M.N., Ambrosino P., Ambrosini F. et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superfi cial vein thrombosis: A systematic review and meta-analysis. J. Thromb. Haemost. 2016;14:964–972. DOI: 10.1111/jth.13279
8. Rabe E., Hoff mann U., Schimke A. et al. Determinants of Late Venous Thromboembolic Events After Acute Isolated Superfi cial Vein Thrombosis in Daily Practice: 12 Month Results of the IN-SIGHTS-SVT Study. Eur. J. Vasc. Endovasc. Surg. 2023;66:697– 704. DOI: 10.1016/j.ejvs.2023.08.031
9. Frappé P., Buchmuller-Cordier A., Bertoletti L. et al. Annual diagnosis rate of superfi cial vein thrombosis of the lower limbs: The STEPH community-based study. J. Thromb. Haemost. 2014;12:831– 838, DOI: 10.1111/jth.12575
10. Geersing G.J., Cazemier S., Rutten F. et al. Incidence of superfi cial venous thrombosis in primary care and risk of subsequent venous thromboembolic sequelae: A retrospective cohort study performed with routine healthcare data from the Netherlands. BMJ Open. 2018;8:e019967. DOI: 10.1136/bmjopen-2017-019967
11. Wiegers H.M.G., Körmendiné Farkas D., Horváth-Puhó E. et al. Incidence and prognosis of superfi cial vein thrombosis during pregnancy and the post-partum period: A Danish nationwide cohort study. Lancet Haematol. 2023;10:e359–e366 DOI: 10.1016/S2352-3026(23)00013-3
12. Grandone E., Tiscia G.L., Ostuni A. et al. Anemone study: Prevalence of risk factors for superfi cial vein thrombosis in a large Italian population of blood donors. J. Thromb. Thrombolysis. 2020;50:689– 696. doi: 10.3390/healthcare12040500
13. Henni S., Ramondou P., Duval G. et al. The risk of lower-limb superfi cial vein thrombosis relative to lower-limb venous thrombotic events is not increased in winter months. Phlebology. 2020;35:533– 537. DOI: 10.1177/0268355519896729
14. Kakkos S.K., Lampropoulos G., Papadoulas S. et al. Seasonal variation in the incidence of superfi cial venous thrombophlebitis. Thromb. Res. 2010;126:98–102. DOI: 10.1016/j.thromres.2010.04.016
15. Frappé P., Bertoletti L., Presles E. et al. Seasonal variation in the superfi cial vein thrombosis frequency. Thromb. Res. 2015;136:1116– 1119. DOI: 10.1016/j.thromres.2015.10.007
16. Torgutalp M., Eroglu D.S., Seze S. et al. Analysis of vascular involvement in 460 patients with Behçet's syndrome: Clinical characteristics and associated factors Joint Bone Spine. 2022;89(2):105277. DOI: 10.1016/j.jbspin.2021.105277
17. Le Joncour A., Soudet S., Dupont A. et al. Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s Disease): A Multicenter Study of 224 Patients. J. Am. Heart Assoc. 2018;7:e010677. DOI: 10.1161/JAHA.118.010677
18. Balahura A.M., A Florescu A.G, Barboi T.M. et al Current Diagnostic and Therapeutic Challenges in Superfi cial Venous Thrombosis. Medicina. 2024;60:1466. DOI: 10.3390/medicina60091466
19. Sobreira M.L., Rogatto S.R., Dos Santos R.M. et al. An unexpectedly high rate of thrombophilia disorders in patients with superfi cial vein thrombosis of the lower extremities. Ann. Vasc. Surg. 2017;43:272– 7. DOI: 10.1016/j.avsg.2017.02.022. PMid:28501666.
20. Lucchi G., Bilancini S., Tucci S., Lucchi M. Superfi cial vein thrombosis in non-varicose veins of the lower limbs and thrombophilia. Phlebology 2018;33:278–281.
21. Hirmerová J., Seidlerová J., Šubrt I., Hajšmanová Z. Prevalence of cancer in patients with superfi cial vein thrombosis and its clinical importance. J. Vasc. Surg. Venous Lymphat. Disord. 2022;10:26–32. DOI: 10.1016/j.jvsv.2021.05.006
22. Langer F., Gerlach H.E., Schimke A. et al. Clinical outcomes of cancer-associated isolated superfi cial vein thrombosis in daily practice. Thromb. Res. 2022;220:145–152. DOI: 10.1016/j.thromres.2022.10.022
23. Galanaud J.P., Sevestre M.A., Pernod G. et al. Long-term risk of venous thromboembolism recurrence after isolated superfi cial vein thrombosis. J. Thromb. Haemost. 2017;15(6):1123–31. DOI: 10.1111/jth.13679. PMid:28317330.
24. Di Nisio M., Peinemann F., Porreca E., Rutjes A.W. Treatment for superfi cial infusion thrombophlebitis of the upper extremity. Cochrane Database Syst. Rev. 2015;2015:CD011015. DOI: 10.1002/14651858. CD011015.pub2
25. Amano M., Shimizu T. Mondor’s disease: A review of the literature. Intern. Med. 2018;57:2607–2612. DOI: 10.2169/internalmedicine.0495-17
26. Salemis NS., Vasilara G., Lagoudianakis E. Mondor’s disease of the breast as a complication of ultrasound-guided core needle biopsy: management and review of the literature. Breast Dis. 2015;35(1):73– 6. DOI: 10.3233/BD-140374. PMid:24989360.
27. Kim Y., Png C.Y.M., Sumpio B.J. et al. Defi ning the human and health care costs of chronic venous insuffi ciency. Semin. Vasc. Surg. 2021;34:59–64. DOI: 10.3390/healthcare12040500
28. Fernandez M.M, Hogue S., Preblick R., Kwong W.J. Review of the cost of venous thromboembolism. Clin. Econ. Outcomes Res. CEOR. 2015;7:451–462. DOI: 10.2147/CEOR.S85635
29. Kiguchi M.M., Fallentine J., Oh J.H. et al. Race, sex, and socioeconomic disparities aff ect the clinical stage of patients presenting for treatment of superfi cial venous disease. Journal of Vascular Surgery. Venous Lymphat. Disord. 2023;11:897–903. DOI: 10.1016/j.jvsv.2023.06.001
30. Decousus H., Quérè I., Presles E. et al. Superfi cial vein thrombosis and venous thromboembolism: A large prospective epidemiological study. Ann. Intern. Med. 2010:152:218–22 DOI: 10.7326/0003-4819-152-4-201002160-00006
31. Galanaud J.P., Genty C., Sevestre M.A. et al. Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superfi cial venous thrombosis. The OPTIMEV study. Thromb. Haemost. 2011105:31–39. DOI: 10.1160/TH10-06-0406
32. Cannegieter S.C., Horváth-Puhó E., Schmidt M. et al. Risk of venous and arterial thrombotic events in patients diagnosed with superfi cial vein thrombosis: A nationwide cohort study. Blood. 2015;125:229– 235. DOI: 10.1182/blood-2014-06-577783
33. Scott G., Mahdi A.J., Alikhan R. Superfi cial vein thrombosis: A current approach to management. Br. J. Haematol. 2015;168:639–645. DOI: 10.1111/bjh.13255
34. Aguilar C., del Villar V. D-dimer is not useful for the diagnosis of isolated superfi cial venous thrombosis. Am. J. Med. 2005;118:1417. e13–1417.e16. DOI: 10.1016/j.amjmed.2005.06.044
35. Sartori M., Migliacci, L., Favarett, E., Cin, M., Legnan, C., Palaret, G., Cosm, B. D-dimer for the diagnosis of upper extremity deep and superfi cial venous thrombosis. Thromb. Res. 2015;135:673–678. DOI: 10.1016/j.thromres.2015.02.007
36. de Almeida M.J. Guillaumon A.T, Miquelin D. et al. Guidelines for superfi cial venous thrombosis. J. Vasc. Bras. 2019;18:e20180105. DOI: 10.1590/1677-5449.180105
37. Boehler K., Kittler H., Stolkovich S., Tzaneva S. Therapeutic effect of compression stockings versus no compression on isolated superfi cial vein thrombosis of the legs: A randomized clinical trial. Eur. J. Vasc. Endovasc. Surg. 2014;48:465–471. DOI: 10.1016/j.ejvs.2014.06.047
38. Kakkos S.K., Gohel M., Baekgaard N. et al. Editor’s Choice—European Society for Vascular Surgery (ESVS) Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur. J. Vasc. Endovasc. Surg. 2021;61:9–82. DOI: 10.1016/j.ejvs.2020.09.023
39. Mosti G., Wittens C., Caggiati A. Black Holes in compression therapy—A quest for data. J. Vasc. Surg. Venous Lymphat. Disord. 2024;12:101733 DOI: 10.1016/j.jvsv.2023.101733
40. Superfi cial Thrombophlebitis Treated by Enoxaparin Study Group. A pilot randomized double-blind comparison of a low molecularweight heparin, a nonsteroidal anti-infl ammatory agent, and placebo in the treatment of superfi cial vein thrombosis. Arch. Intern. Med. 2003;163:1657–1663. DOI: 10.1001/archinte.163.14.1657
41. Di Nisio M., Wichers I.M., Middeldorp S. Treatment for superfi cial thrombophlebitis of the leg. Cochrane Database Syst. Rev. 2018;2:CD004982. DOI: 10.1002/14651858.CD004982.pub6
42. Mangiafi co M., Caff ,A., Costanzo L. The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. J. Clin. Med. 2022;11:3099. DOI: 10.3390/jcm11113099
43. Marchiori A., Verlato F., Sabbion P. et al High versus low doses of unfractionated heparin for the treatment of superfi cial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica. 2002;87:523–527.
44. Prandoni P., Tormene D., Pesavento R. Vesalio Investigators Group. High vs. low doses of low-molecular-weight heparin for the treatment of superfi cial vein thrombosis of the legs: A double-blind, randomized trial. J. Thromb. Haemost. 2005;3:1152–1157. DOI: 10.1111/j.1538-7836.2005.01391.x
45. Cosmi B., Filippini M., Tonti D. et al. STEFLUX Investigators. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superfi cial vein thrombosis: STEFLUX (Superfi cial ThromboEmbolism and Fluxum). J. Thromb. Haemost. 2012;10:1026–1035. DOI: 10.1111/j.1538-7836.2012.04727.x
46. Nikolakopoulos K.M., Kakkos S.K., Papageorgopoulou C.P., Tsolakis I.A. Extended-Duration Treatment of Superfi cial Vein Thrombosis of the Lower Limbs with Tinzaparin. Vasc. Spec. Int. 2018;34:1–9. DOI: 10.5758/vsi.2018.34.1.1
47. Karathanos C., Kakkos S.K., Georgiadis G. et al. SeVEN Collaborators. Risk of recurrent thromboembolic events according to treatment duration in patients with superfi cial vein thrombosis treated with intermediate dose of tinzaparin. Phlebology 2023;38:141–149. DOI: 10.1177/02683555221143576
48. Prandoni P., Pesavento R., Bilora F. et al. No diff erence in outcome between therapeutic and preventive anticoagulation in patients with superfi cial vein thrombosis involving the saphenous-femoral junction. Vasc. Med. 2022;27:290–292. DOI: 10.1177/1358863X211066962
49. Leizorovicz A., Becker F., Buchmuller A. et al. Clinical relevance of symptomatic superfi cial-vein thrombosis extension: lessons from the CALISTO study. Blood. 2013;122(10):1724–9. DOI: 10.1182/blood-2013-04-498014.
50. Stevens S.M., Woller S.C., Kreuziger L.B. et al. Antithrombotic Therapy for VTE Disease. Chest. 2021;160:e545–e608, Erratum in Chest 2022;162:269. DOI: 10.1016/j.chest.2021.07.055
51. Beyer-Westendorf J., Schellong., S.M., Gerlach H. et al. SURPRISE Investigators. Prevention of thromboembolic complications in patients with superfi cial-vein thrombosis given rivaroxaban or fondaparinux: The open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017;4:e105–e113. DOI: 10.1016/S2352-3026(17)30014-5
52. Kearon C., Carrier M., Gu C.S. et al. Rivaroxaban Compared to Placebo for the Treatment of Leg Superfi cial Vein Thrombosis: A Randomized Trial. Semin. Thromb. Hemost. 2020;46:977–985. DOI: 10.1055/s-0040-1718891
53. Beyer-Westendorf J. Controversies in venous thromboembolism: To treat or not to treat superfi cial vein thrombosis. Hematol. Am. Soc. Hematol. Educ. Program 2017. 2017:223–230. DOI: 10.1182/asheducation-2017.1.223
54. Sullivan V., Denk PM., Sonnad S.S. et al. Ligation versus anticoagulation: treatment of above-knee superfi cial thrombophlebitis not involving the deep venous system. J. Am. Coll. Surg. 2001;193:556– 62. DOI: 10.1016/s1072-7515(01)01043-2
55. Lozano F.S., Almazan A Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc. Endovascular. Surg. 2003;37(6):415–20. DOI: 10.1177/153857440303700605.
56. BontinisV., BontinisA., Koutsoumpelis A. et al. Endovenous thermal ablation in the treatment of large great saphenous veins of diameters > 12 mm: A systematic review meta-analysis and meta-regression. Vascular Medicine. 2023;28:5:449–457. DOI: 0000-0001-5349-5367
57. Kearon C., Akl E.A., Comerota A.J., Prandoni P. et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl):e419S-94S DOI: 10.1378/chest.11-2301
58. Bates S.M., Rajasekhar A ., Middeldorp S. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood adv. 2018;2(22):3317–3359. DOI: 10.1182/bloodadvances.2018024802
59. VTE in Pregnancy Guideline Working Group. Venous thromboembolism and antithrombotic therapy in pregnancy. J. Obstet. Gynaecol. Can. 2014;36:527–53 DOI: 10.1016/s1701-2163(15)30569-7
60. Scovell S.D., Ergul E.A., Mark F. Conrad M F. Medical management of acute superfi cial vein thrombosis of the saphenous vein. J. Vasc. Surg: Venous and Lym. Dis. 2018;6:109–17. DOI: 10.1016/j.jvsv.2017.08.016
61. Camporese G., Di Micco P., Di Nisio M. et al on behalf of SIAPAV Members. Common Practice in the Treatment of Superfi cial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV). Medicina. 2023;59:1068. DOI: 10.3390/medicina59061068
62. Ellis M.H., Fajer S. A current approach to superfi cial vein thrombosis. Eur. J. Haematol. 2013;90:85–88. DOI: 10.1111/ejh.12044
63. Bauersachs R., Gerlach H.E., Heinken A., Hoff mann U., Langer F., Noppeney T., Pittrow D., Klotsche J., Rabe E. Management and Outcomes of Patients with Isolated Superfi cial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT). Eur. J. Vasc. Endovasc. Surg. 2021;62:241–249. DOI: 10.1016/j.ejvs.2021.04.015
64. van Royen F.S., van Smeden M., Moons K.G.M., Rutten F.H., Geersing G.J. Management of superfi cial venous thrombosis based on individual risk profi les: Protocol for the development and validation of three prognostic prediction models in large primary care cohorts. Diagn. Progn. Res. 2021;5:15. DOI: 10.1186/s41512-021-00104-8
65. Hingorani A., Ascher E. Superfi cial venous thrombophlebitis. In: Gloviczki P, editor. Handbook of venous disorders guidelines of the American Venous Forum. 3rd ed. London: Hodder Arnold; 2009:314–9. DOI DOI: 10.1201/9780429072789
Review
For citations:
Sugraliyev A.B. Tactics of management of superficial vein thrombosis. Clinical Medicine (Russian Journal). 2026;104(3):184-194. (In Russ.) https://doi.org/10.30629/0023-2149-2026-104-3-184-194
Views:
128
JATS XML
Email this article 